These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 35151843)
1. Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. Chevillard C; Amen A; Besson S; Hannani D; Bally I; Dettling V; Gout E; Moreau CJ; Buisson M; Gallet S; Fenel D; Vassal-Stermann E; Schoehn G; Poignard P; Dagher MC; Fender P Mol Ther; 2022 May; 30(5):1913-1925. PubMed ID: 35151843 [TBL] [Abstract][Full Text] [Related]
2. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964 [TBL] [Abstract][Full Text] [Related]
3. Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice. Pflumm D; Seidel A; Klein F; Groß R; Krutzke L; Kochanek S; Kroschel J; Münch J; Stifter K; Schirmbeck R Front Immunol; 2023; 14():1231274. PubMed ID: 37753087 [TBL] [Abstract][Full Text] [Related]
4. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927 [TBL] [Abstract][Full Text] [Related]
5. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development. Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067 [TBL] [Abstract][Full Text] [Related]
6. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L Front Immunol; 2021; 12():697074. PubMed ID: 34262569 [TBL] [Abstract][Full Text] [Related]
7. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
9. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]
10. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response. Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888 [TBL] [Abstract][Full Text] [Related]
11. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
12. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
15. Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2. Dicks MDJ; Rose LM; Russell RA; Bowman LAH; Graham C; Jimenez-Guardeño JM; Doores KJ; Malim MH; Draper SJ; Howarth M; Biswas S Mol Ther; 2022 Dec; 30(12):3639-3657. PubMed ID: 35949171 [TBL] [Abstract][Full Text] [Related]
16. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
17. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347 [TBL] [Abstract][Full Text] [Related]
18. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Lin WS; Chen IC; Chen HC; Lee YC; Wu SC Front Immunol; 2021; 12():795741. PubMed ID: 34925381 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Luo S; Zhang P; Liu B; Yang C; Liang C; Wang Q; Zhang L; Tang X; Li J; Hou S; Zeng J; Fu Y; Allain JP; Li T; Zhang Y; Li C Emerg Microbes Infect; 2021 Dec; 10(1):1002-1015. PubMed ID: 33993845 [No Abstract] [Full Text] [Related] [Next] [New Search]